Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06999408Not ApplicableActive Not Recruiting

Efficacy and Safety of TargetCool + Benev Exosomes in Patients With Hair Thinning

Role: collaborator

NCT06616311Not ApplicableCompleted

Efficacy of Radiofrequency Micro Needling for the Treatment of Melasma in Skin of Color.

Role: collaborator

NCT06571799Not ApplicableCompleted

Study Evaluating the Efficacy and Safety of BENEV Exosome Regenerative Complex+ for Self-perceived Thinning Hair

Role: collaborator

NCT06415435Not ApplicableRecruiting

Sylfirm X Radiofrequency Microneedling for the Treatment of Melasma

Role: lead

All 4 trials loaded